share_log

Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $9

Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $9

查丹資本維持對Pear Therapeutics的買入,將目標股價下調至9美元
Benzinga Real-time News ·  2022/08/12 09:04

Chardan Capital analyst Keay Nakae maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $13 to $9.

Chardan Capital分析師Keay Nakae維持Pear Therapeutics(納斯達克股票代碼:PEAR)的買入並將目標股價從13美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論